Etiology, Presentation, and Risk Factors for Diarrheal Syndromes in 3 Sub-Saharan African Countries After the Introduction of Rotavirus Vaccines From the Vaccine Impact on Diarrhea in Africa (VIDA) Study.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
19 04 2023
Historique:
medline: 21 4 2023
pubmed: 19 4 2023
entrez: 19 04 2023
Statut: ppublish

Résumé

Diarrheal disease is heterogeneous, including watery diarrhea (WD) and dysentery, some cases of which become persistent diarrhea (PD). Changes in risk over time necessitate updated knowledge of these syndromes in sub-Saharan Africa. The Vaccine Impact on Diarrhea in Africa (VIDA) study was an age-stratified, case-control study of moderate-to-severe diarrhea among children <5 years old in The Gambia, Mali, and Kenya (2015-2018). We analyzed cases with follow-up of about 60 days after enrollment to detect PD (lasting ≥14 days), examined the features of WD and dysentery, and examined determinants for progression to and sequelae from PD. Data were compared with those from the Global Enteric Multicenter Study (GEMS) to detect temporal changes. Etiology was assessed from stool samples using pathogen attributable fractions (AFs), and predictors were assessed using χ2 tests or multivariate regression, where appropriate. Among 4606 children with moderate-to-severe diarrhea, 3895 (84.6%) had WD and 711 (15.4%) had dysentery. PD was more frequent among infants (11.3%) than in children 12-23 months (9.9%) or 24-59 months (7.3%), P = .001 and higher in Kenya (15.5%) than in The Gambia (9.3%) or Mali (4.3%), P < .001; the frequencies were similar among children with WD (9.7%) and those with dysentery (9.4%). Compared to children not treated with antibiotics, those who received antibiotics had a lower frequency of PD overall (7.4% vs 10.1%, P = .01), and particularly among those with WD (6.3% vs 10.0%; P = .01) but not among children with dysentery (8.5% vs 11.0%; P = .27). For those with watery PD, Cryptosporidium and norovirus had the highest AFs among infants (0.16 and 0.12, respectively), while Shigella had the highest AF (0.25) in older children. The odds of PD decreased significantly over time in Mali and Kenya while increasing significantly in The Gambia. The burden of PD endures in sub-Saharan Africa, with nearly 10% of episodes of WD and dysentery becoming persistent.

Sections du résumé

BACKGROUND
Diarrheal disease is heterogeneous, including watery diarrhea (WD) and dysentery, some cases of which become persistent diarrhea (PD). Changes in risk over time necessitate updated knowledge of these syndromes in sub-Saharan Africa.
METHODS
The Vaccine Impact on Diarrhea in Africa (VIDA) study was an age-stratified, case-control study of moderate-to-severe diarrhea among children <5 years old in The Gambia, Mali, and Kenya (2015-2018). We analyzed cases with follow-up of about 60 days after enrollment to detect PD (lasting ≥14 days), examined the features of WD and dysentery, and examined determinants for progression to and sequelae from PD. Data were compared with those from the Global Enteric Multicenter Study (GEMS) to detect temporal changes. Etiology was assessed from stool samples using pathogen attributable fractions (AFs), and predictors were assessed using χ2 tests or multivariate regression, where appropriate.
RESULTS
Among 4606 children with moderate-to-severe diarrhea, 3895 (84.6%) had WD and 711 (15.4%) had dysentery. PD was more frequent among infants (11.3%) than in children 12-23 months (9.9%) or 24-59 months (7.3%), P = .001 and higher in Kenya (15.5%) than in The Gambia (9.3%) or Mali (4.3%), P < .001; the frequencies were similar among children with WD (9.7%) and those with dysentery (9.4%). Compared to children not treated with antibiotics, those who received antibiotics had a lower frequency of PD overall (7.4% vs 10.1%, P = .01), and particularly among those with WD (6.3% vs 10.0%; P = .01) but not among children with dysentery (8.5% vs 11.0%; P = .27). For those with watery PD, Cryptosporidium and norovirus had the highest AFs among infants (0.16 and 0.12, respectively), while Shigella had the highest AF (0.25) in older children. The odds of PD decreased significantly over time in Mali and Kenya while increasing significantly in The Gambia.
CONCLUSIONS
The burden of PD endures in sub-Saharan Africa, with nearly 10% of episodes of WD and dysentery becoming persistent.

Identifiants

pubmed: 37074436
pii: 7130317
doi: 10.1093/cid/ciad022
pmc: PMC10116565
doi:

Substances chimiques

Rotavirus Vaccines 0
Anti-Bacterial Agents 0

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

S12-S22

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Déclaration de conflit d'intérêts

Potential conflicts of interest. S. M. T. reports multiple grants paid to her institution from the National Institutes of Health, the Bill & Melinda Gates Foundation, Wellcome Trust, Affinivax, Lumen Biosciences, PATH, and the Medical Research Council. S. M. T. also reports payments as royalties related to intellectual property for Salmonella vaccines and Klebsiella/Pseudomonas vaccines; consulting fees and travel support from the University of Washington for a grant proposal; multiple planned, issued, and pending patents on Salmonella, Klebsiella, and Pseudomonas vaccines; and multiple unpaid committee roles with the American Society of Tropical Medicine and Hygiene. K. L. K. reports consultation fees and travel support from PATH and the University of Washington related to diarrheal diseases and grant support to her institution from the National Institute of Allergy and Infections Diseases, Institut Pasteur, and the Bill & Melinda Gates Foundation. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Références

Scand J Infect Dis. 1990;22(3):259-67
pubmed: 2371542
Lancet. 2020 Oct 17;396(10258):1223-1249
pubmed: 33069327
J Infect Dis. 1997 Jun;175(6):1527-30
pubmed: 9180200
Clin Infect Dis. 2012 Dec;55 Suppl 4:S232-45
pubmed: 23169936
J Infect Dis. 2000 May;181(5):1643-51
pubmed: 10823764
BMC Public Health. 2021 Oct 23;21(1):1926
pubmed: 34688267
PLoS One. 2013 May 29;8(5):e64636
pubmed: 23734210
Gastroenterology. 2010 Oct;139(4):1156-64
pubmed: 20638937
Am J Epidemiol. 1997 Aug 1;146(3):273-82
pubmed: 9247012
Am J Trop Med Hyg. 2017 Jul;97(1):248-258
pubmed: 28719331
BMC Pediatr. 2022 Jul 1;22(1):385
pubmed: 35778675
J Infect Dis. 2021 Dec 20;224(12 Suppl 2):S848-S855
pubmed: 34528677
Acta Paediatr Suppl. 1992 Sep;381:15-21
pubmed: 1421934
Clin Infect Dis. 2012 Dec;55 Suppl 4:S246-53
pubmed: 23169937
Trans R Soc Trop Med Hyg. 1999 Jan-Feb;93(1):65-8
pubmed: 10492794
Pediatr Infect Dis J. 1993 Sep;12(9):751-61; discussion 762-4
pubmed: 8414804
Paediatr Int Child Health. 2018 May;38(2):87-96
pubmed: 28475437
Lancet. 2021 Sep 4;398(10303):870-905
pubmed: 34416195
J Glob Health. 2019 Dec;9(2):020801
pubmed: 31673345
Pediatrics. 1984 Jun;73(6):799-805
pubmed: 6374599
PLoS One. 2010 Apr 28;5(4):e10386
pubmed: 20442848
Clin Infect Dis. 2023 Apr 19;76(Supplement_1):S5-S11
pubmed: 37074428
Bull World Health Organ. 1988;66(6):709-17
pubmed: 3266111
Acta Paediatr (Stockh). 1992 Sep;81 Suppl 381:3-6
pubmed: 12286021
Lancet. 2013 Jul 20;382(9888):209-22
pubmed: 23680352
Lancet. 2016 Sep 24;388(10051):1291-301
pubmed: 27673470
Lancet. 1988 Sep 3;2(8610):552-5
pubmed: 2900931
PLoS One. 2012;7(5):e36436
pubmed: 22590543
Int J Epidemiol. 1990 Sep;19(3):728-35
pubmed: 2262271
Cell Microbiol. 2019 Nov;21(11):e13067
pubmed: 31194282
BMC Infect Dis. 2016 Sep 06;16:477
pubmed: 27600526
Lancet. 1989 Aug 5;2(8658):319-22
pubmed: 2569114
Indian J Pediatr. 2012 Apr;79(4):472-7
pubmed: 21948223
Turk J Pediatr. 2009 Mar-Apr;51(2):133-40
pubmed: 19480324
Clin Infect Dis. 2012 Dec;55 Suppl 4:S294-302
pubmed: 23169941
Acta Paediatr. 2012 Oct;101(10):e452-7
pubmed: 22734659
EBioMedicine. 2021 Apr;66:103310
pubmed: 33862589
Lancet Glob Health. 2019 May;7(5):e568-e584
pubmed: 31000128
JAMA. 2016 Jun 28;315(24):2712-23
pubmed: 27357241
Vaccines (Basel). 2022 Mar 07;10(3):
pubmed: 35335035
J Pediatr Gastroenterol Nutr. 1991 Jan;12(1):82-8
pubmed: 2061784
Am J Trop Med Hyg. 1999 Nov;61(5):707-13
pubmed: 10586898
J Pediatr Gastroenterol Nutr. 2008 Aug;47(2):260-5
pubmed: 18664885
Am J Epidemiol. 1990 Jul;132(1):144-56
pubmed: 2192547
Indian J Gastroenterol. 2001 Mar-Apr;20(2):59-61
pubmed: 11305492
Am J Trop Med Hyg. 2003 Jun;68(6):671-7
pubmed: 12892051

Auteurs

Andrea G Buchwald (AG)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Jennifer R Verani (JR)

Division of Global Health Protection, Centers for Disease Control and Prevention, Nairobi, Kenya.

Adama Mamby Keita (AM)

Centre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali.

M Jahangir Hossain (M)

Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

Anna Roose (A)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Samba O Sow (SO)

Centre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali.

Richard Omore (R)

Kenya Medical Research Institute, Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya.

Sanogo Doh (S)

Centre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali.

Joquina Chiquita M Jones (JCM)

Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

Dilruba Nasrin (D)

Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Syed M A Zaman (SMA)

Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

Catherine Okoi (C)

Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

Martin Antonio (M)

Medical Research Council Unit The Gambia at the London School of Hygiene & Tropical Medicine, Banjul, The Gambia.

John B Ochieng (JB)

Kenya Medical Research Institute, Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya.

Jane Juma (J)

Kenya Medical Research Institute, Center for Global Health Research (KEMRI-CGHR), Kisumu, Kenya.

Uma Onwuchekwa (U)

Centre pour le Développement des Vaccins du Mali (CVD-Mali), Bamako, Mali.

Helen Powell (H)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.

James A Platts-Mills (JA)

Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.

Sharon M Tennant (SM)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Karen L Kotloff (KL)

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH